TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive In Brief: Appropriations Bill Hung Up In Senate; Paul Black To Head B.U. Humphrey Center September 21, 1979
TCL Archive High Response Rate of Hairy Cell Leukemia Patients to Immunotoxin Treatment In Phase I April 27, 2001
